Related references
Note: Only part of the references are listed.Risk of arterial thrombotic and venous thromboembolic events in patients with primary chronic immune thrombocytopenia: a Scandinavian population-based cohort study
Mette Norgaard et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial
Waleed Ghanima et al.
LANCET (2015)
Are adverse drug reaction patterns different between romiplostim and eltrombopag? 2009-2013 French PharmacoVigilance assessment
Guillaume Moulis et al.
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2014)
Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors
M. Ruggeri et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2014)
Immune thrombocytopenia in the elderly: clinical course in 525 patients from a single center in China
Hu Zhou et al.
ANNALS OF HEMATOLOGY (2013)
Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study
Mansoor N. Saleh et al.
BLOOD (2013)
Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia
Soames Boyle et al.
BLOOD (2013)
Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group
Francesco Rodeghiero et al.
BLOOD (2013)
Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy
David J. Kuter et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials
Francesco Rodeghiero et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2013)
Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years
Nicola Vianelli et al.
HAEMATOLOGICA (2013)
Function of eltrombopag-induced platelets compared to platelets from control patients with immune thrombocytopenia
Johanna Haselboeck et al.
THROMBOSIS AND HAEMOSTASIS (2013)
In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation
Bethan Psaila et al.
BLOOD (2012)
Risk of arterial thrombosis in patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study
Mette Norgaard et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Short- and long-term risks of splenectomy for benign haematological disorders: should we revisit the indications?
Francesco Rodeghiero et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program
Mehdi Khellaf et al.
BLOOD (2011)
The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia
Cindy Neunert et al.
BLOOD (2011)
Risk of venous thromboembolism in patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study
Marianne T. Severinsen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
ITP: a historical perspective
Roberto Stasi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
International consensus report on the investigation and management of primary immune thrombocytopenia
Drew Provan et al.
BLOOD (2010)
Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database
Ameet Sarpatwari et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Comorbidities in patients with persistent or chronic immune thrombocytopenia
Cheryl Enger et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2010)
Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group
Francesco Rodeghiero et al.
BLOOD (2009)
Vascular complications after splenectomy for hematologic disorders
Shelley E. Crary et al.
BLOOD (2009)
Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production
Diane Nugent et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Is splenectomy still the gold standard for the treatment of chronic ITP?
Francesco Rodeghiero et al.
AMERICAN JOURNAL OF HEMATOLOGY (2008)
Incidence and mortality of venous thrombosis:: a population-based study
I. A. Naess et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)
S Miyakis et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2006)
Long-term outcomes in adults with chronic ITP after splenectomy failure
R McMillan et al.
BLOOD (2004)
Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies
LM Aledort et al.
AMERICAN JOURNAL OF HEMATOLOGY (2004)
Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications
K Kojouri et al.
BLOOD (2004)
Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura:: a prospective cohort study
R Diz-Küçükkaya et al.
BLOOD (2001)
Share Paper
